Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 212-218

  Zaorsky, Nicholas G ^a   Studenski, Matthew T ^a   Dicker, Adam P ^a   Gomella, Leonard ^a   Den, Robert B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Hypofractionation; Prostate cancer; Quality of life; Radiotherapy; Stereotactic body radiation therapy; Toxicity

Indexed keywords

CELL DEATH; COLLIMATOR; COMPUTED TOMOGRAPHY SCANNER; DOSIMETRY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RADIATION DOSE; RADIATION PHYSICS; RADIOBIOLOGY; RESOURCE ALLOCATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; UROGENITAL TRACT DISEASE;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOSURGERY; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84873994847     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.10.003     Document Type: Review

References (91)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29. Jan-Feb 2012.
2. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):67-74.
3. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):980-988.
4. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239.
5. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therpay in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American college of radiology 95-09. J Clin Oncol 2010, 28(7):1106-1111.
6. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol Jun 2007, 8(6):475-487.
7. Dandapani S.V., Sanda M.G. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol Jan 2008, 18(1):67-72.
8. Bhatta-Dhar N., Reuther A.M., Zippe C., Klein E.A. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology Mar 2004, 63(3):528-531.
9. Boorjian S.A., Karnes R.J., Rangel L.J., Bergstralh E.J., Blute M.L. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol Apr 2008, 179(4):1354-1360. (Discussion 1360-1351).
10. Kane C.J., Im R., Amling C.L., et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance. results from the SEARCH database. Urology Sep 2010, 76(3):695-700.
11. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72Gy, external beam radiotherapy > or =72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58(1):25-33.
12. Nguyen P.L., Chen M.H., Catalona W.J., et al. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer 2008, 113(11):3146-3152.
13. Weight C.J., Reuther A.M., Gunn P.W., Zippe C.R., Dhar N.B., Klein E.A. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10years after radical prostatectomy in patients with low-risk prostate cancer. Urology Jan 2008, 71(1):141-145.
14. Menon M., Bhandari M., Gupta N., et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol Dec 2010, 58(6):838-846.
15. Bittner N., Merrick G.S., Galbreath R.W., et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008, 72(2):433-440.
16. Burri R.J., Ho A.Y., Forsythe K., Cesaretti J.A., Stone N.N., Stock R.G. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77(5):1315-1321.
17. Critz F.A., Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol Dec 2004, 172(6 Pt 1):2232-2238.
18. Hinnen K.A., Battermann J.J., van Roermund J.G., et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys Apr 2010, 76(5):1433-1438.
19. Jabbari S., Weinberg V.K., Shinohara K., et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010, 76(1):36-42.
20. Martin A.G., Roy J., Beaulieu L., Pouliot J., Harel F., Vigneault E. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: a 12-year Canadian experience. Int J Radiat Oncol Biol Phys 2007, 67(2):334-341.
21. Merrick G.S., Butler W.M., Wallner K.E., Galbreath R.W., Allen Z.A., Adamovich E. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy. Urology Nov 2005, 66(5):1048-1053.
22. Merrick G.S., Butler W.M., Wallner K.E., Galbreath R.W., Allen Z.A., Adamovich E. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65(3):669-677.
23. Morris W.J., Keyes M., Palma D., et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urol Apr 2009, 73(4):860-865. (Discussion 865-867).
24. Moyad M.A., Merrick G.S., Butler W.M., et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology Dec 2005, 66(6):1150-1154.
25. Pickles T., Keyes M., Morris W.J. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys 2010, 76(1):43-49.
26. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol May 2008, 179(5 Suppl):S20-24.
27. Stone N.N., Stock R.G., Cesaretti J.A., Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010, 76(2):355-360.
28. Taira A.V., Merrick G.S., Galbreath R.W., Wallner K.E., Butler W.M. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76(2):349-354.
29. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67(2):327-333.
30. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67(1):65-70.
31. Ip S, Dvorak T, Yu WW et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update. In: (AHRQ) AfHRaQ, ed2010.
32. Fuller D.B., Lee C., Hardy S., Jin H. Virtual HDR Cyberknife prostate treatment: toward the development of Non-invasive HDR dosimetry delivery and early clinical observations. Int J Radiat Oncol Biol Phys 2007, 69(3):s358.
33. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001, 50(4):1021-1031.
34. Wang J.Z., Li X.A. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys 2005, 61(1):220-227.
35. Fowler J.F., Ritter M.A., Chappell R.J., Brenner D.J. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 56(4):1093-1104.
36. Brenner D.J., Martinez A.A., Edmundson G.K., Mitchell C., Thames H.D., Armour E.P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13.
37. Potters L., Kavanagh B., Galvin J.M., et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 76(2):326-332.
38. Munoz F., Fiandra C., Franco P., et al. Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med (Torino) 2012.
39. Wierzbicki M., Schaly B., Peters T., Barnett R. Automatic image guidance for prostate IMRT using low dose CBCT. Med Phys Jul 2010, 37(7):3677-3686.
40. Klayton T., Price R., Buyyounouski M.K. Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys Feb 11 2012.
41. Cavalieri R., Gay H.A., Liu J., et al. Total error shift patterns for daily CT on rails image-guided radiotherapy to the prostate bed. Radiat Oncol 2011, 6:142.
42. Graf R., Boehmer D., Budach V., Wust P. Interfraction rotation of the prostate as evaluated by kilovoltage X-ray fiducial marker imaging in intensity-modulated radiotherapy of localized prostate cancer. Med Dosim Apr 23 2012.
43. Owen R., Kron T., Foroudi F., Milner A., Cox J., Duchesne G. Interfraction prostate rotation determined from in-room computerized tomography images. Med Dosim Summer 2011, 36(2):188-194.
44. Li J.S., Jin L., Pollack A., et al. Gains from real-time tracking of prostate motion during external beam radiation therapy. Int J Radiat Oncol Biol Phys 2009, 75(5):1613-1620.
45. Litzenberg D.W., Balter J.M., Hadley S.W., et al. Prostate intrafraction translation margins for real-time monitoring and correction strategies. Prostate Cancer 2012, 2012:130579.
46. Amro H., Hamstra D.A., McShan D.L. The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy. Int J Radiat Oncol Biol Phys May 2 2012.
47. Holmboe E.S., Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med Oct 2000, 15(10):694-701.
48. Parthan A., Pruttivarasin N., Taylor D., et al. CyberKnife for prostate cancer: is it cost-effective? Genitourinary cancers symposium. J Clin Oncol 2011, suppl 7:abstr 87.
49. Perez C.A., Kobeissi B., Smith B.D., et al. Cost accounting in radiation oncology: a computer-based model for reimbursement. Int J Radiat Oncol Biol Phys 1993, 25(5):895-906.
50. Lievens Y., van den Bogaert W., Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57(2):522-535.
51. Norlund A. Costs of radiotherapy. Acta Oncol 2003, 42(5-6):411-415.
52. Van de Werf E., Lievens Y., Verstraete J., Pauwels K., Van den Bogaert W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother Oncol Oct 2009, 93(1):137-140.
53. Kesteloot K., Lievens Y., van der Schueren E. Improved management of radiotherapy departments through accurate cost data. Radiother Oncol Jun 2000, 55(3):251-262.
54. Hanks G.E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr 1988, 7:75-84.
55. Zagars G.K., von Eschenbach A.C., Johnson D.E., Oswald M.J. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys Apr 1988, 14(4):701-709.
56. Duncan W., Warde P., Catton C.N., et al. Carcinoma of the prostate: results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 1993, 26(2):203-210.
57. Read G., Pointon R.C. Retrospective study of radiotherapy in early carcinoma of the prostate. Br J Urol Feb 1989, 63(2):191-195.
58. Kearsley J.H. High-dose radiotherapy for localized prostatic cancer. An analysis of treatment results and early complications. Med J Aust 1986, 144(12):624-628.
59. Preston C.I., Duncan W., Kerr G.R. Radical treatment of prostatic carcinoma by megavoltage X-ray therapy. Clin Radiol Sep 1986, 37(5):473-477.
60. Miles E.F., Lee W.R. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol Jan 2008, 18(1):41-47.
61. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23(25):6132-6138.
62. Yeoh E.E., Botten R.J., Butters J., Di Matteo A.C., Holloway R.H., Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81(5):1271-1278.
63. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006, 66(4):1072-1083.
64. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(1):11-18.
65. Arcangeli G., Fowler J., Gomellini S., et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1013-1021.
66. Arcangeli S., Strigari L., Gomellini S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012.
67. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64(2):518-526.
68. Pollack A., Walker G., Buyyounouski M., et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81(2):S1.
69. Kuban D.A., Nogueras-Gonzalez G.M., Hamblin L., et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010, 78(3):S58-S59.
70. Kupelian P.A., Willoughby T.R., Reddy C.A., Klein E.A., Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68(5):1424-1430.
71. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol Jan 2012, 13(1):43-54.
72. Hossain S., Xia P., Chuang C., et al. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys Sep 2008, 35(9):4041-4048.
73. Madsen B.L., Hsi R.A., Pham H.T., Fowler J.F., Esagui L., Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67(4):1099-1105.
74. Tang C.I., Loblaw D.A., Cheung P., et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol) Dec 2008, 20(10):729-737.
75. Quon H, Cheung P, Cesta A et al. Phase II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localized prostate cancer: Toxicity results of pHART3. Paper presented at: Genitourinary Cancers, Symposium. 2010.
76. Aluwini S., van Rooij P., Hoogeman M., et al. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol May 2010, 24(5):865-869.
77. Mantz CA, Fernandez E, Zucker I, Harrison S. A Phase II Trial of Real-time Target Tracking SBRT for Low-risk Prostate Cancer Utilizing the Calypso 4D Localization System: Patient-reported Quality of Life and Toxicity Outcomes. Paper presented at: ASTRO 20112011; Fort Myers, FL.
78. Katz A.J., Santoro M., DiBlasio F., Ashley R. Stereotactic body radiation therapy for low-, intermediate- and high-risk prostate cancer: disease control and quality of life. Int J Radiat Oncol Biol Phys 2011, 81:S100.
79. Katz A.J., Santoro M., Ashley R., Diblasio F., Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat Dec 2010, 9(6):575-582.
80. King C.R., Brooks J.D., Gill H., Presti J.C. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):877-882.
81. Friedland J.L., Freeman D.E., Masterson-McGary M.E., Spellberg D.M. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat Oct 2009, 8(5):387-392.
82. McBride S.M., Wong D.S., Dombrowski J.J., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011.
83. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29(15):2020-2026.
84. Bolzicco G., Favretto M.S., Scremin E., Tambone C., Tasca A., Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat Oct 2010, 9(5):473-477.
85. Fuller DB, Shirazi R, Naitoh J, Mardirossian G. Virtual HDR SBRT for localized prostate carcinoma: Efficacy and quality-of-life assessment. J Clin Oncol 2012(30):suppl 5; abstr 45.
86. Kang J.K., Cho C.K., Choi C.W., et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori Jan-Feb 2011, 97(1):43-48.
87. Jabbari S., Weinberg V.K., Kaprealian T., et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82(1):228-234.
88. Lukka H. RTOG 0938: A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer-RTOG CCOP Study. 2011. <>. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0938.
89. Denham J.W., O'Brien P.C., Dunstan R.H., et al. Is there more than one late radiation proctitis syndrome?. Radiother Oncol Apr 1999, 51(1):43-53.
90. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358(12):1250-1261.
91. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol Jun 2007, 177(6):2106-2131.